3.94

2.47% 0.09

Mannkind Corp (MNKD)

Overview News Price History Option Chain Financials Why MNKD Down? Discussions Forecast Stock Split

Mannkind Corp stock is traded at $3.94, with a volume of 883.23K. It is up +2.47% in the last 24 hours and up +3.54% over the past month. MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.

Previous Close:

$3.85

Open:

$3.94

24h Volume:

883.23K

Relative Volume:

0.37

Market Cap:

$1.20B

Revenue:

$248.37M

Net Income/Loss:

$11.74M

P/E Ratio:

78.80

EPS:

0.05

Net Cash Flow:

$18.24M

1W Performance:

+3.27%

1M Performance:

+3.54%

6M Performance:

-34.36%

1Y Performance:

-34.25%

1-Day Range:

$3.90

$4.00

1-Week Range:

$3.73

$4.05

52-Week Range:

$3.51

$7.63

Mannkind Corp Stock (MNKD) Company Profile

Name

Mannkind Corp

Sector

Healthcare (1173)

Industry

Biotechnology (654)

Phone

818-661-5000

Address

1 CASPER STREET, DANBURY, CA

Employee

407

Twitter

@MannKindCorp

Next Earnings Date

2024-11-07

Latest SEC Filings

MNKD's Discussions on Twitter

Compare MNKD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MNKD Mannkind Corp	3.945	1.10B	248.37M	11.74M	18.24M	0.05
VRTX Vertex Pharmaceuticals Inc	468.44	119.76B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	555.39	59.14B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	319.34	41.40B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	573.55	32.96B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	279.22	26.46B	3.81B	-644.79M	-669.77M	-6.24

Mannkind Corp Stock (MNKD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-25	Initiated	Mizuho	Outperform
Feb-10-25	Initiated	Wedbush	Outperform
Dec-20-24	Initiated	Wells Fargo	Overweight
Dec-19-24	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Sep-09-24	Resumed	Leerink Partners	Outperform
Jun-13-24	Initiated	Rodman & Renshaw	Buy
Oct-10-23	Initiated	Wedbush	Outperform
May-14-21	Initiated	RBC Capital Mkts	Sector Perform
Dec-24-19	Initiated	Oppenheimer	Outperform
Oct-25-19	Initiated	Cantor Fitzgerald	Overweight
May-14-19	Initiated	BTIG Research	Buy
Mar-04-19	Initiated	SVB Leerink	Outperform
Feb-22-19	Initiated	SVB Leerink	Outperform
Feb-28-18	Downgrade	Maxim Group	Hold → Sell
Nov-01-17	Downgrade	Maxim Group	Buy → Hold
Oct-10-17	Initiated	H.C. Wainwright	Buy
Oct-06-17	Reiterated	Maxim Group	Buy
Aug-11-17	Initiated	Maxim Group	Buy
May-10-16	Reiterated	Piper Jaffray	Underweight
May-10-16	Reiterated	RBC Capital Mkts	Underperform
Jan-06-16	Reiterated	Piper Jaffray	Underweight
Jan-06-16	Reiterated	RBC Capital Mkts	Underperform
Nov-04-15	Downgrade	RBC Capital Mkts	Outperform → Underperform
Sep-09-15	Downgrade	Piper Jaffray	Neutral → Underweight
Aug-03-15	Reiterated	RBC Capital Mkts	Outperform
May-11-15	Downgrade	JP Morgan	Neutral → Underweight
May-11-15	Reiterated	MLV & Co	Hold
Apr-16-15	Reiterated	RBC Capital Mkts	Outperform

View All

Mannkind Corp Stock (MNKD) Latest News

07:32 AM

H.C. Wainwright assumes coverage on MannKind stock with Buy rating - Investing.com

07:32 AM

Jul 15, 2025

What makes MannKind Corporation stock price move sharplyLow Risk Scalping Alerts - Newser

Jul 15, 2025

Why MannKind Corporation stock attracts strong analyst attentionGrowth Stock Monitor - Newser

Jul 15, 2025

Jul 14, 2025

High Growth Tech Stocks To Watch In The US July 2025 - Yahoo Finance

Jul 14, 2025

Jul 11, 2025

Wells Fargo Maintains a Buy Rating on MannKind Corporation (MNKD), Sets a $9 PT - Yahoo Finance

Jul 11, 2025

Leerink Partners Slashes MannKind Corporation’s (MNKD) Price Target to $7, Keeps a Buy Rating - Yahoo Finance

Jun 24, 2025

Jun 23, 2025

MannKind (MNKD) Presents Pediatric Insulin Trial Data - Yahoo Finance

Jun 23, 2025

Jun 17, 2025

MannKind stock hits 52-week low at $3.70 - Investing.com

Jun 17, 2025

Jun 11, 2025

Top 3 Health Care Stocks That May Rocket Higher This Quarter - Benzinga

Jun 11, 2025

Jun 10, 2025

Insider Sell: Steven Binder Sells 64,085 Shares of MannKind Corp (MNKD) - GuruFocus

Jun 10, 2025

MannKind director Steven Binder sells $256,340 in shares By Investing.com - Investing.com South Africa

Jun 10, 2025

MannKind director Steven Binder sells $256,340 in shares - Investing.com Australia

Jun 10, 2025

Phase II home run: Insmed’s TPIP hits hypertension endpoints - BioWorld MedTech

Jun 10, 2025

MannKind stock touches 52-week low at $4.04 amid market shifts - Investing.com Nigeria

Jun 10, 2025

Jun 09, 2025

MannKind to present inhaled insulin study at ADA event By Investing.com - Investing.com Canada

Jun 09, 2025

MannKind to present inhaled insulin study at ADA event - Investing.com

Jun 09, 2025

Breakthrough in Pediatric Diabetes Care: MannKind Phase 3 Trial Data Reveals New Inhaled Insulin Treatment Option - Stock Titan

Jun 09, 2025

Jun 05, 2025

MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation By Investing.com - Investing.com Canada

Jun 05, 2025

MannKind at Jefferies Global Healthcare: Strategic Growth and Innovation - Investing.com Australia

Jun 05, 2025

MannKind To Present At Jefferies Global Healthcare Conference; Webcast At 2:35 PM ET - Nasdaq

Jun 05, 2025

May 28, 2025

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit - Seeking Alpha

May 28, 2025

May 27, 2025

Type 1 Diabetes Didn't Stop This INDYCAR Driver: Conor Daly Inspires Detroit Youth Before Grand Prix - Stock Titan

May 27, 2025

MannKind: Why I'm Still Bullish Despite Tyvaso DPI Competition - Seeking Alpha

May 27, 2025

May 23, 2025